INVO Bioscience Inc stock (US44984F1049): Nasdaq notice on late 10-Q filing and FY 2025 update

INVO Bioscience Inc, now operating as INVO Fertility and listed on Nasdaq in the United States under ticker IVF, has disclosed a Nasdaq delinquency notice over a late Form 10-Q filing and reported modest revenue growth for fiscal 2025.

INVO Bioscience Inc, which now conducts business as INVO Fertility in the United States, drew fresh investor attention on 06/02/2026 after announcing that Nasdaq has notified the company of a delinquency related to its late filing of the Quarterly Report on Form 10-Q, while investors continue to digest recently released fiscal 2025 results.

In a press release dated 06/02/2026, INVO Fertility said it received a Nasdaq notice on 05/27/2026 due to the company not yet having filed its Form 10-Q for the quarter ended 03/31/2026, a requirement under Nasdaq Listing Rules, according to GlobeNewswire as of 06/02/2026.

The company stated that the notification does not immediately affect the listing or trading of its shares on Nasdaq in the United States, but it triggers a defined timetable for INVO Fertility to regain compliance by submitting the delayed report or submitting a plan, as described in the same release.

Management attributed the delay in the 10-Q filing primarily to the time and resources required to complete its Form 10-K for the year ended 12/31/2025, which was recently filed with the U.S. Securities and Exchange Commission, as indicated in the Nasdaq notice release.

On the same day, INVO Fertility also highlighted its fiscal year 2025 performance, noting that revenue rose to USD 6,841,250, which represented growth of about 5% compared with USD 6,532,000 for fiscal 2024, according to a separate results release dated 06/02/2026 from GlobeNewswire as of 06/02/2026.

The company reported that consolidated clinic revenue, which reflects fertility clinic operations, increased 4% to USD 6,721,057 in fiscal 2025 from USD 6,450,431 a year earlier, underscoring that the core services business is still expanding even as the company faces ongoing losses.

INVO Fertility remains headquartered in the United States and is listed on Nasdaq under the ticker IVF, which provides U.S. investors with direct access to the stock in their home currency, U.S. dollars, while the Nasdaq notice emphasizes the importance of timely reporting under U.S. securities regulation.

According to price data on 06/02/2026, the stock traded around USD 1.62 on Nasdaq, up roughly 10% on the day, with MarketBeat citing a session move of plus 0.16 dollars as of the U.S. afternoon session, based on information from MarketBeat as of 06/02/2026.

MarketBeat data also show that shares of INVO Fertility were priced near USD 3.76 at the start of 2026 and have since declined by more than half to roughly USD 1.62, illustrating the volatility that has characterized the stock in recent months.

In Germany, where some investors follow U.S.-listed small caps via secondary venues, INVO Fertility can be accessed on platforms such as Tradegate under the U.S. listing, typically quoted in euros, although trading volumes are materially lower than on Nasdaq.

The latest regulatory notice from Nasdaq adds another layer of complexity to the investment narrative for INVO Fertility, which has already disclosed substantial doubt about its ability to continue as a going concern in its recent annual report due to cumulative net losses and reliance on external financing, as highlighted in its Form 10-K summary reported by StockTitan on 04/01/2026.

As of: 03/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: INVO Bioscience Inc
• Sector/industry: Fertility healthcare services and reproductive medicine
• Headquarters/country: Sarasota, United States
• Core markets: U.S. fertility clinics with selective international distribution for its fertility treatment solutions
• Key revenue drivers: Revenue from owned and managed fertility clinics, patient treatment cycles, and related fertility services
• Home exchange/listing venue: Nasdaq (IVF)
• Trading currency: USD

INVO Bioscience Inc: core business model

Operating under the name INVO Fertility, the company focuses on fertility clinic operations centered around its intravaginal culture and assisted reproductive technologies, generating most of its revenue from patient treatments and clinic-based fertility services rather than from device sales alone.

INVO Bioscience Inc in peer comparison

For context, INVO Fertility competes in the broader fertility and reproductive health space alongside larger U.S.-listed operators such as Progyny and Kindbody-related vehicles, though those peers generally have significantly higher market capitalizations and broader benefit-management or technology platforms.

Progyny, for example, reported revenue of USD 1.17 billion for fiscal 2024 according to its 02/27/2025 earnings release, compared with INVO Fertility’s USD 6.84 million in fiscal 2025 revenue, highlighting the scale difference between specialized benefit managers and smaller clinic-focused operators in the United States.

In addition, Align Technology, while primarily known for orthodontics rather than fertility treatments, offers another comparison point in terms of medical-technology-enabled patient services and reported USD 3.9 billion in 2024 net revenues in its 01/31/2025 update, underscoring how niche a player INVO Fertility remains within the broader medical services segment.

Conclusion

The latest Nasdaq notification about INVO Fertility’s delayed 10-Q filing keeps regulatory compliance in focus just as the company reports a 5% year-on-year revenue increase for fiscal 2025 and modest growth in clinic revenue.

Against a backdrop of a sharply lower share price over the past year and earlier going-concern language in its annual report, the combination of filing delays and small-scale growth places renewed emphasis on liquidity, execution at its clinics, and the timing of future U.S. regulatory filings.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.